Enalapril maleateCAS# 76095-16-4 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 76095-16-4 | SDF | Download SDF |
| PubChem ID | 5388961 | Appearance | Powder |
| Formula | C24H32N2O9 | M.Wt | 492.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (101.52 mM) H2O : 33.33 mg/mL (67.67 mM; Need ultrasonic and warming) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (Z)-but-2-enedioic acid;(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid | ||
| SMILES | CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O.C(=CC(=O)O)C(=O)O | ||
| Standard InChIKey | OYFJQPXVCSSHAI-QFPUQLAESA-N | ||
| Standard InChI | InChI=1S/C20H28N2O5.C4H4O4/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25;5-3(6)1-2-4(7)8/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25);1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,16-,17-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Enalapril maleate Dilution Calculator
Enalapril maleate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0305 mL | 10.1523 mL | 20.3046 mL | 40.6091 mL | 50.7614 mL |
| 5 mM | 0.4061 mL | 2.0305 mL | 4.0609 mL | 8.1218 mL | 10.1523 mL |
| 10 mM | 0.203 mL | 1.0152 mL | 2.0305 mL | 4.0609 mL | 5.0761 mL |
| 50 mM | 0.0406 mL | 0.203 mL | 0.4061 mL | 0.8122 mL | 1.0152 mL |
| 100 mM | 0.0203 mL | 0.1015 mL | 0.203 mL | 0.4061 mL | 0.5076 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Enalapril Maleate, the active metabolite of enalapril, is an angiotensin-converting enzyme (ACE) inhibitor. Target: ACE Enalapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to enalaprilat following oral administration. Enalaprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Enalapril may be used to treat essential or renovascular hypertension and symptomatic congestive heart failure [1].
References:
[1]. Liu, Y.H., et al., Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice. J Cardiovasc Pharmacol, 2006. 47(1): p. 82-8.
- SCH 28080
Catalog No.:BCC7154
CAS No.:76081-98-6
- Artocarpin
Catalog No.:BCN4309
CAS No.:7608-44-8
- Myricoside
Catalog No.:BCC8342
CAS No.:76076-04-5
- 1-Dehydro-6-gingerdione
Catalog No.:BCN3265
CAS No.:76060-35-0
- Broussonin C
Catalog No.:BCN4588
CAS No.:76045-49-3
- 3-Epikatonic acid
Catalog No.:BCN4308
CAS No.:76035-62-6
- Lanatin
Catalog No.:BCC8194
CAS No.:76026-24-9
- H-DL-Nva-OH
Catalog No.:BCC3303
CAS No.:760-78-1
- Conopharyngine
Catalog No.:BCN3975
CAS No.:76-98-2
- Mepenzolate Bromide
Catalog No.:BCC3809
CAS No.:76-90-4
- Trityl Chloride
Catalog No.:BCC2805
CAS No.:76-83-5
- Tephrosin
Catalog No.:BCN4742
CAS No.:76-80-2
- Hederacoside D
Catalog No.:BCN2330
CAS No.:760961-03-3
- Solithromycin
Catalog No.:BCC6446
CAS No.:760981-83-7
- Phaseollidin hydrate
Catalog No.:BCN3962
CAS No.:76122-57-1
- 7-Hydroxy-DPAT hydrobromide
Catalog No.:BCC6756
CAS No.:76135-30-3
- 8-Hydroxy-DPAT hydrobromide
Catalog No.:BCC6681
CAS No.:76135-31-4
- Glucosylvitexin
Catalog No.:BCN5929
CAS No.:76135-82-5
- Ipragliflozin
Catalog No.:BCC5137
CAS No.:761423-87-4
- ALK inhibitor 1
Catalog No.:BCC1339
CAS No.:761436-81-1
- TAE226 (NVP-TAE226)
Catalog No.:BCC3885
CAS No.:761437-28-9
- ALK inhibitor 2
Catalog No.:BCC1340
CAS No.:761438-38-4
- TAE684 (NVP-TAE684)
Catalog No.:BCC3660
CAS No.:761439-42-3
- Mildronate
Catalog No.:BCC2289
CAS No.:76144-81-5
Pulmonary artery banding in a cat with a perimembranous ventricular septal defect and left-sided congestive heart failure.[Pubmed:30835177]
J Am Vet Med Assoc. 2019 Mar 15;254(6):723-727.
CASE DESCRIPTION A 6-month-old sexually intact male domestic shorthair cat was referred for evaluation of a heart murmur and ventricular septal defect (VSD). CLINICAL FINDINGS Physical examination revealed a grade 5/6 right apical systolic heart murmur. Findings on thoracic radiography were consistent with moderate right and left ventricular enlargement, left atrial enlargement, and enlargement of the pulmonary arteries and veins; an interstitial pulmonary pattern was also evident. Echocardiography revealed a perimembranous VSD with left-to-right shunting combined with trace mitral valve regurgitation. The cat later developed a dry cough, the intensity of the heart murmur increased to grade 6/6, and signs of left-sided congestive heart failure developed. TREATMENT AND OUTCOME Medical treatment included Enalapril maleate and furosemide. When the cat's condition worsened despite medical treatment, palliative pulmonary artery banding was performed. During surgery, blood pressure in the pulmonary artery was measured with a pulmonary artery catheter, and pulmonary artery banding was successfully achieved with a polytetrafluoroethylene band and hemoclips. The pulmonary-to-systemic blood flow ratio was reduced from 3 to 1.5, and signs of congestive heart failure resolved within 2 weeks after surgery. CLINICAL RELEVANCE Findings suggested that cats with a VSD and pulmonary-to-systemic flow ratio > 3 or with congestive heart failure attributable to a VSD could be considered candidates for palliative pulmonary artery banding to alleviate clinical signs. However, further investigation into long-term prognosis with objective outcome measurements and with multiple cases is needed. (J Am Vet Med Assoc 2019;254:723-727).
